VivoSeq
Oncology

Diffuse Large B-Cell Lymphoma

283

Pipeline Programs↗

113

Active Trials↗

88

Companies Involved↗

Diffuse Large B-Cell Lymphoma is a highly competitive landscape with 283 programs across 88 companies. The most active players are Xynomic Pharmaceuticals, Inc., Beijing Yongtai Ruike Biotechnology Company Ltd, Jiangsu Topcel-KH Pharmaceutical Co., Ltd.. 10 therapies are approved with 79 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

87/100

Pipeline Velocity

50/100

Mech. Concentration

5/100

Completion Rate

64/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

X

Xynomic Pharmaceuticals, Inc.

1 program

Phase 1B

Beijing Yongtai Ruike Biotechnology Company Ltd

1 program

Phase 1J

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

1 program

Phase 1Sun Pharma logo

Sun Pharma

1 program

Phase 1UCB logo

UCB

1 program

Phase 1K

Kenvue Brands

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical18

Tisagenlecleucel

Novartis

Lisocabtagene Maraleucel

Bristol-Myers Squibb

Axicabtagene Ciloleucel

Gilead

Ocrelizumab

Roche

Polatuzumab Vedotin

Roche

Phase 139

Fludarabine Phosphate

Sanofi

TAZEMETOSTAT

Epizyme, Inc.

Alisertib

Takeda

Atezolizumab

Roche

Duvelisib

SecuraBio

Phase 2137

Epcoritamab

Genmab

Idecabtagene Vicleucel

Bristol-Myers Squibb

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Venetoclax

AbbVie

Blinatumomab

Amgen

Phase 379

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Brentuximab Vedotin

Pfizer

Glofitamab

Roche

Orelabrutinib

Beijing InnoCare Pharma Tech Co., Ltd.

Methylprednisolone

Pfizer

Approved10

Panobinostat

SecuraBio

Fostamatinib

Rigel Pharmaceuticals

Vinorelbine

Pierre Fabre Medicament

Ixabepilone

R-Pharm

Umbralisib

TG Therapeutics, Inc.

Analysis

Modality Breakdown

78%

Small molecule

244 of 311 classified programs — the dominant modality here.

22%ALL OTHERSMonoclonal antibody3411%Cell therapy124%Protein / enzyme103%Antibody–drug conjugate72%Radiopharmaceutical2<1%RNA therapy1<1%Other1<1%

Small molecule leads; the ring shows all 311 classified programs, each share of the total. Modality classified for 97% of 333 pipeline programs.

Analysis

Trial Status

353

clinical trials

Completed124 · 35%
Recruiting53 · 15%
Terminated51 · 14%
Active, not recruiting45 · 13%
Unknown status44 · 12%
Withdrawn18 · 5%
Other18 · 5%

Clinical Trials

Trial Activity

353 trials

R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT06594640·108 enrolled
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Recruiting·RRanok Therapeutics (Hangzhou) Co., Ltd.·Phase 1/2·NCT05487170·32 enrolled
Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma
Recruiting·—·Phase 2·NCT05422066·50 enrolled
Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
Recruiting·TThe Lymphoma Academic Research Organisation·Phase 2·NCT06931652·60 enrolled
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
Recruiting·—·Phase 2·NCT06828991·40 enrolled
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06765317·42 enrolled
Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma
Recruiting·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 2·NCT07254754·45 enrolled
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Recruiting·XXynomic Pharmaceuticals, Inc.·Phase 2·NCT03936153·170 enrolled
A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma
Recruiting·SShandong Cancer Hospital and Institute·Phase 2·NCT05933967·31 enrolled
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
Recruiting·WWashington University School of Medicine·Phase 2·NCT06687772·36 enrolled
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
Recruiting·AADC Therapeutics S.A.·Phase 1·NCT05660395·56 enrolled
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Recruiting·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 3·NCT06521255·244 enrolled
Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Recruiting·MMehrdad Abedi, MD·Phase 1·NCT05052528·36 enrolled
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Recruiting·SWOG Cancer Research Network·Phase 2·NCT05633615·396 enrolled
Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
Recruiting·BBeijing Yongtai Ruike Biotechnology Company Ltd·Phase 1·NCT06047197·25 enrolled
Page 1 of 24

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)